Published in Asian J Androl on February 15, 2010
The influence of age on bioavailable and free testosterone is independent of body mass index and glucose levels. World J Urol (2011) 0.84
Low-dose testosterone treatment decreases oxidative damage in TM3 Leydig cells. Asian J Androl (2011) 0.82
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med (2004) 5.68
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2006) 5.58
Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab (2002) 4.46
Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab (2000) 4.34
Low serum testosterone and mortality in older men. J Clin Endocrinol Metab (2007) 4.27
Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation (2007) 3.71
Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67
The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res (1994) 3.52
Aging of skeletal muscle: a 12-yr longitudinal study. J Appl Physiol (1985) (2000) 3.47
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab (2010) 3.15
Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci (2005) 3.14
The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev (2005) 3.11
Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab (2004) 3.02
Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol (2009) 2.96
Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med (2007) 2.88
Prevalence and risk factors for erectile dysfunction in the US. Am J Med (2007) 2.84
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab (1999) 2.79
Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab (2002) 2.76
Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab (2004) 2.73
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab (2004) 2.72
Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab (1997) 2.71
Androgens and cardiovascular disease. Endocr Rev (2003) 2.71
Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab (2000) 2.68
Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) (2005) 2.63
Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc (2007) 2.63
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A (1997) 2.54
Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care (2005) 2.52
Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab (2004) 2.47
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol (2006) 2.46
Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev (1999) 2.39
Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab (2000) 2.36
Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab (2004) 2.35
Low serum testosterone and mortality in male veterans. Arch Intern Med (2006) 2.28
Androgens and coronary artery disease. Endocr Rev (2003) 2.26
Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol (2004) 2.14
Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab (1992) 1.94
The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol (2003) 1.89
Sex steroids and bone. Physiol Rev (2001) 1.88
Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab (1999) 1.84
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol (2004) 1.82
The relationship between muscle mass and muscle strength in the elderly. J Am Geriatr Soc (1991) 1.80
Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol (2007) 1.79
Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab (2006) 1.78
Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab (2007) 1.77
Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol (2007) 1.75
Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation (2000) 1.71
The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract (2008) 1.69
Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism (1990) 1.63
Hematocrit and the risk of coronary heart disease mortality. Am Heart J (2001) 1.62
Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol (2006) 1.62
Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab (1996) 1.57
The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract (2006) 1.56
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab (1997) 1.54
Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab (1998) 1.51
Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab (1999) 1.50
Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis (2001) 1.49
Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia (2008) 1.48
Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer (2007) 1.48
Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation (1988) 1.47
The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb (1994) 1.46
Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab (2006) 1.44
Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation (2004) 1.43
Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab (2004) 1.42
Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int (2006) 1.41
Obstructive sleep apnea: implications for cardiac and vascular disease. Chest (2008) 1.36
Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab (2007) 1.36
Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab (1999) 1.35
Testosterone replacement therapy: current trends and future directions. Hum Reprod Update (2004) 1.33
The endocrinology of sexual arousal. J Endocrinol (2005) 1.30
Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med (2008) 1.29
Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc (1993) 1.29
The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. J Clin Endocrinol Metab (2008) 1.29
Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab (2005) 1.28
Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry (2001) 1.28
Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology (2005) 1.28
The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl (2008) 1.27
Sex hormones and cognitive function in older men. J Am Geriatr Soc (2002) 1.26
Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab (1999) 1.25
Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab (2007) 1.25
Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol (2004) 1.25
Testosterone replacement therapy after primary treatment for prostate cancer. J Urol (2005) 1.25
Occult prostate cancer in men with low serum testosterone levels. JAMA (1996) 1.24
Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc (2003) 1.24
Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol (2005) 1.24
The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl (2008) 1.23
Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol (2008) 1.21
The health of normally aging men: The Massachusetts Male Aging Study (1987-2004). Exp Gerontol (2004) 1.21
Hormones and prostate cancer: what's next? Epidemiol Rev (2001) 1.20
Predictive accuracy and sources of variability in calculated free testosterone estimates. Ann Clin Biochem (2009) 1.20
Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol (2004) 1.19
Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. J Clin Endocrinol Metab (1996) 1.18
Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab (2003) 1.16
Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology (2004) 1.13
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res (2005) 1.12
Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) (2003) 1.12
Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs (2005) 1.12
Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol (2009) 1.10